Why Is BridgeBio Pharma Stock Trading Higher On Friday? - BridgeBio Pharma ( NASDAQ:BBIO )
Friday, BridgeBio Pharma Inc. BBIO presented additional data from an analysis of its Phase 3 ATTRibute-CM and open-label extension study of acoramidis in ATTR-CM at the European Society of Cardiology ( ESC ) 2024.
| Ticker |
Sentiment |
Impact |
|
BBIO
|
Neutral
|
43 %
|
|
BAYZF
|
Somewhat Bullish
|
15 %
|
|
PFE
|
Neutral
|
30 %
|
